Altamira Therapeutics Launches Public Offering
Ticker: CYTOF · Form: 6-K · Filed: Sep 19, 2024 · CIK: 1601936
Sentiment: neutral
Topics: public-offering, capital-raise, pharmaceutical
TL;DR
Altamira Therapeutics is doing a public offering as of Sept 17, 2024.
AI Summary
On September 17, 2024, Altamira Therapeutics Ltd. initiated a best efforts public offering. The company, formerly known as Auris Medical Holding Ltd., is a pharmaceutical preparations company incorporated in Bermuda.
Why It Matters
This public offering indicates Altamira Therapeutics is seeking to raise capital, which could fund further research, development, or expansion of its pharmaceutical products.
Risk Assessment
Risk Level: medium — Public offerings can be subject to market conditions and investor sentiment, and the success of the offering will impact the company's future funding.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Registrant
- Auris Medical Holding Ltd. (company) — Former company name
- September 17, 2024 (date) — Start date of public offering
FAQ
What is the purpose of the public offering initiated by Altamira Therapeutics?
The filing states that Altamira Therapeutics commenced a 'best efforts public offering' on September 17, 2024, indicating a capital-raising initiative, though the specific use of funds is not detailed in this excerpt.
When did Altamira Therapeutics begin its public offering?
Altamira Therapeutics commenced its best efforts public offering on September 17, 2024.
What was Altamira Therapeutics' former name?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd., with previous name changes also noted for Auris Medical Holding AG and Auris Medical Holding Ltd.
Under which SEC form is this report filed?
This report is filed under Form 6-K, which is a Report of Foreign Private Issuer.
What is the primary business of Altamira Therapeutics?
Altamira Therapeutics Ltd. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 1,703 words · 7 min read · ~6 pages · Grade level 13.9 · Accepted 2024-09-19 16:17:07
Key Financial Figures
- $0.002 — Shares”) common shares, par value $0.002 per share, of the Company (the “C
- $0 — ach Share and accompanying Warrants was $0.72, and the public offering price for e
- $0.718 — d Warrant and accompanying Warrants was $0.718. The Pre-Funded Warrants have an exerci
- $0.72 — The Warrants have an exercise price of $0.72 per share and are exercisable immediate
- $3.3 million — rrants and Warrants, were approximately $3.3 million. The potential additional gross proceed
- $8.0 million — on a cash basis, will be approximately $8.0 million. No assurance can be given that any of
- $100,000 — s received in the Offering, (iii) up to $100,000 for fees and expenses of the Placement
- $20,000 — a non-accountable expense allowance of $20,000 and (v) $15,950 for the clearing expens
- $15,950 — le expense allowance of $20,000 and (v) $15,950 for the clearing expenses. Also pursua
- $0.90 — gent Warrants have an exercise price of $0.90 per share and expire on September 17, 2
- $9.00 — or in July 2023 at an exercise price of $9.00 per Common Share and with an expiration
Filing Documents
- ea0215114-6k_altamira.htm (6-K) — 28KB
- ea021511401ex4-1_altamira.htm (EX-4.1) — 95KB
- ea021511401ex4-2_altamira.htm (EX-4.2) — 102KB
- ea021511401ex4-3_altamira.htm (EX-4.3) — 102KB
- ea021511401ex4-4_altamira.htm (EX-4.4) — 98KB
- ea021511401ex10-1_altamira.htm (EX-10.1) — 247KB
- ea021511401ex10-2_altamira.htm (EX-10.2) — 8KB
- ea021511401ex99-1_altamira.htm (EX-99.1) — 15KB
- ea021511401ex99-2_altamira.htm (EX-99.2) — 14KB
- 0001213900-24-080300.txt ( ) — 711KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Altamira Therapeutics Ltd. Date: September 19, 2024 By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer 4